Imatinib (INN) is a frontline tyrosine-kinase inhibitor notably used in the targeted therapy of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) by targeting BCR-Abl-expressing leukemic cells. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.